The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study

Annals of Gastroenterology

Volumn 30, Issue 6, 2017, Pages 654-663

  Verhaeghe, Laurens ^a   Bruyneel, Luk ^b   Stragier, Elisabeth ^a   Ferrante, Marc ^a   Dierickx, Daan ^a   Prenen, Hans ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Leuven Institute for Healthcare Policy   (Belgium)

Author keywords

Digestive oncology; Hepcidin; Intravenous iron; Iron deficiency anemia

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; HEPCIDIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG UNDERDOSE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

EID: 85033387016     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: 10.20524/aog.2017.0189     Document Type: Article

References (30)

1. Cancer- and chemotherapy-induced anemia. NCCN Guidelines Version 1.2018 – June 23, 2017.
2. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-973.
3. Lind M, Vernon C, Cruickshank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86:1243-1249.
4. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009;12:60-63.
5. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis and mortality in hospitalized cancer patients. Arch Intern Med 2008;168:2377-2381.
6. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
7. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
8. Verraes K, Prenen H. Iron deficiency in gastrointestinal oncology. Ann Gastroenterol 2015;28:19-24.
9. Rizzo JD, Brouwers M, Hurley P, et al; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
10. Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007;35:167-172.
11. Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013;24:1886-1892.
12. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2016;2:CD009624.
13. Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 2014;22:2197-2206.
14. Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199-204.
15. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116:522-525.
16. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 2013;131:679-682.
17. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-482.
18. Toledano A, Luporsi E, Morere JF, et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 2016;24:67-75.
19. Hedenus M, Karlsson T, Ludwig H, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 2014;31:302.
20. Hallet J, Hanif A, Callum J, et al. The impact of perioperative iron on the use of red blood cell transfusions in gastrointestinal surgery: a systematic review and meta-analysis. Transfus Med Rev 2014;28:205-211.
21. Ng O, Keeler BD, Mishra A, et al. Iron therapy for pre-operative anaemia. Cochrane Database Syst Rev 2015;22:CD011588.
22. Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015;125:3669-3671.
23. Shu T, Jing C, Lv Z, Xie Y, Xu J, Wu J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol 2015;94:67-73.
24. Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia 2015;2015:763576.
25. Muñoz M, García-Erce JA, Remacha F. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011;64:287-296.
26. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion 2012;52:1584-1592.
27. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.
28. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-1076.
29. th ed. McGraw-Hill press: New York, NY; 2010, pp. 617-624.
30. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther 2011;5:51-60.